We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychi... Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. Show more
Enrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024 USPTO grants additional method of use patent for ganaxolone in TSC Marinus...
ZTALMY® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 Increased full year 2024 projected U.S. ZTALMY net product revenues to between...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release...
Trial did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024 Future...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.07 | -5.03597122302 | 1.39 | 1.46 | 1.3 | 1235877 | 1.33042246 | CS |
4 | -0.09 | -6.3829787234 | 1.41 | 1.77 | 1.3 | 1635364 | 1.42424267 | CS |
12 | -8.24 | -86.1924686192 | 9.56 | 10.5 | 1.11 | 2113021 | 2.49844602 | CS |
26 | -4.77 | -78.3251231527 | 6.09 | 11.26 | 1.11 | 1208944 | 3.66705662 | CS |
52 | -7.26 | -84.6153846154 | 8.58 | 11.26 | 1.11 | 961105 | 5.43474737 | CS |
156 | -14 | -91.3838120104 | 15.32 | 19.83 | 1.11 | 545769 | 6.56829351 | CS |
260 | -3.27 | -71.2418300654 | 4.59 | 20.04 | 0.77 | 1034891 | 4.46639681 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions